InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (9 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
9
T+90 hit rate
67%
T+90 mean return
-0.4%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Parsey Merdad, Directeur Médical. Director active across 4 companies, notably Gilead Sciences INC. Aggregated, 38 reports have been recorded. Split: 0 buy · 9 sells. Total volume traded: €2.2m. Activity tracked since 15 August 2021. The latest transaction was disclosed on 28 April 2025 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations38 total
26,455 sharesCommon StockSEC:0001792150-26-000002:0
42,056 shares0Common StockSEC:0001628280-25-025641:0
3,820 sharesCommon StockSEC:0001127602-24-029171:0
57,294 shares@ US$57.9239.2% of flowCommon StockSEC:0001127602-24-028232:0
25,000 shares@ US$57.9216.4% of flowCommon StockSEC:0001127602-24-026735:0
2,000 shares@ US$83.831.9% of flowCommon StockSEC:0001127602-24-024958:0
25,000 shares@ US$57.9216.2% of flowCommon StockSEC:0001127602-24-023946:0
3,821 sharesCommon StockSEC:0001127602-24-023821:0
2,000 shares@ US$68.631.6% of flowCommon StockSEC:0001127602-24-019650:0
3,820 sharesCommon StockSEC:0001127602-24-018413:0
2,000 shares@ US$72.961.7% of flowCommon StockSEC:0001127602-24-011987:0
3,455 sharesCommon StockSEC:0001127602-24-009546:0
2,000 shares@ US$73.181.7% of flowCommon StockSEC:0001127602-24-007678:0
20,229 shares0Common StockSEC:0001127602-24-003044:0
2,779 sharesCommon StockSEC:0001127602-23-029247:0
1,501 shares@ US$76.991.3% of flowCommon StockSEC:0001127602-23-024115:0
2,779 sharesCommon StockSEC:0001127602-23-023979:0
8,677 sharesCommon StockSEC:0001104659-23-082729:0
1,485 shares@ US$76.901.3% of flowCommon StockSEC:0001127602-23-018727:0
2,779 sharesCommon StockSEC:0001127602-23-018588:0
6,126 shares@ US$78.995.6% of flowCommon StockSEC:0001127602-23-010126:0
3,455 sharesCommon StockSEC:0001127602-23-009986:0
12,984 shares@ US$79.961912.2% of flowCommon StockSEC:0001127602-23-008491:0
376 shares@ US$56.38050.2% of flowCommon StockSEC:0001127602-23-006763:0
29,644 shares0Common StockSEC:0001127602-23-002286:0
25 of 38 declarations
About Parsey Merdad
Merdad Parsey is the Chief Medical Officer at Gilead Sciences Inc. He is responsible for the company's medical strategy, including research and development of new treatments. His expertise is crucial for innovation in the pharmaceutical sector.
